GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2012-04-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 343
- Registration Number
- NCT00395317
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab
- Conditions
- Lymphoma, Follicular
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 116
- Registration Number
- NCT00394836
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)
- Conditions
- Irritable Bowel Syndrome (IBS)
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT00394186
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: GSK716155 subcutaneous injections
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 63
- Registration Number
- NCT00394030
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss.
- Conditions
- Tinnitus
- Interventions
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT00394056
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 57
- Registration Number
- NCT00393146
- Locations
- 🇪🇸
GSK Investigational Site, Santiago de Compostela, Spain
A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)
- Conditions
- Pulmonary Disease, Chronic ObstructiveChronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00392587
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
- Conditions
- Schizophrenia
- Interventions
- Procedure: pet/spect scan
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2012-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00392743
- Locations
- 🇪🇸
GSK Investigational Site, Sant Boi de Llobregat, Spain
Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants
- Conditions
- Infections, Streptococcal
- Interventions
- Biological: Pneumococcal conjugate vaccine GSK1024850ABiological: Infanrix hexa
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 286
- Registration Number
- NCT00390910
- Locations
- 🇪🇸
GSK Investigational Site, Móstoles/Madrid, Spain
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Drug: HYCAMTIN, oral capsulesRadiation: Radiation
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2014-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 472
- Registration Number
- NCT00390806
- Locations
- 🇸🇰
GSK Investigational Site, Nitra, Slovakia